Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium

被引:205
作者
Creasman, WT
Kohler, MF
Odicino, F
Maisonneuve, P
Boyle, P
机构
[1] Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA
[2] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy
关键词
uterine papillary serous carcinoma; clear cell carcinoma; grade 3 stage I carcinoma;
D O I
10.1016/j.ygyno.2004.08.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer. Methods. The 25th Annual Report (AR) of FIGO was used to identify patients with endometrial cancers who were surgically staged. For comparison, all cancers reported were evaluated with particular interest in patients with stage I UPSC, CC, and G3. Incidence, substage, post-surgical treatment, and survival were identified. Results. Of 5694 endometrial cancer patients reported to the AR, 3996 (70%) were surgically stage I. There were 148 UPSC, 59 CC, and 325 with G3 lesions. UPSC and CC represent 5.2% of all stage I cancers while 8.1% are G3. Although there were greater number of UPSC, CC, and G3 with extrauterine disease, about 50% of UPSC and CC were stage I. This compares to 81% for G1, 68% for G2, and only 42% for G3. There were more IA cancers with UPSC and CC than G3 (22%, 33%, and 17%, respectively). Survival (5 years) for UPSC and CC was 72% and 81%, respectively, compared to 76% for G3 lesions. Postoperative radiation improved survival somewhat (6-8%) but the difference was not significant. Conclusion. UPSC and CC histotypes when diagnosed as stage I have a better survival than commonly perceived and equal to G3 endometrioid cancers. Postoperative radiation improves survival but not significantly so. The role of chemotherapy has not been defined. (C) 2004 Published by Elsevier Inc.
引用
收藏
页码:593 / 596
页数:4
相关论文
共 11 条
  • [1] [Anonymous], P AM SOC CLIN ONCOLO
  • [2] BORUDA D, 2003, P AN M AM SOC CLIN, V22, P456
  • [3] CHAMBERS JT, 2001, P AN M AM SOC CLIN, V82, P156
  • [4] The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma
    Cirisano, FD
    Robboy, SJ
    Dodge, RK
    Bentley, RC
    Krigman, HR
    Synan, IS
    Soper, JT
    Clarke-Pearson, DL
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 77 (01) : 55 - 65
  • [5] Creasman W T, 2001, J Epidemiol Biostat, V6, P47
  • [6] UTERINE PAPILLARY SEROUS CARCINOMA - A HIGHLY MALIGNANT FORM OF ENDOMETRIAL ADENOCARCINOMA
    HENDRICKSON, M
    ROSS, J
    EIFEL, P
    MARTINEZ, A
    KEMPSON, R
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (02) : 93 - 108
  • [7] LAUCHLAN SC, 1981, ARCH PATHOL LAB MED, V105, P615
  • [8] Treatment of uterine papillary serous carcinoma with paclitaxel
    Ramondetta, L
    Burke, TW
    Levenback, C
    Bevers, M
    Bodurka-Bevers, D
    Gershenson, DM
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (01) : 156 - 161
  • [9] Neoadjuvant chemotherapy in uterine papillary serous carcinoma
    Resnik, E
    Taxy, JB
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 62 (01) : 123 - 127
  • [10] STEED HL, 2003, P AN M AM SOC CLIN, V22, P453